If so, you may qualify for a narcolepsy clinical research study looking to find a new treatment option to help improve wakefulness.
TAK-994 is an investigational drug that, if approved, will be the first treatment of its kind. This oral treatment targets OX deficiency, working differently from approved Narcolepsy medications. OX deficiency plays an important role in Excessive Daytime Sleepiness (EDS), a common symptom associated with Narcolepsy.
By addressing OX deficiency, TAK-994 may address many symptoms associated with Narcolepsy.
Early study data shows that participants who received TAK-994 as part of the study, when compared to placebo (inactive drug) and baseline experienced:
While it is too early to draw any definitive conclusions, this early data suggests that the TAK-994 study drug may offer an important improvement in effectiveness compared to currently approved therapies.
This could represent a significant improvement in wakefulness and alertness as well as an improved quality of life for people living with narcolepsy.